Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
11.00
-0.10 (-0.90%)
At close: Jan 8, 2026
19.31%
Market Cap758.68M
Revenue (ttm)n/a
Net Income (ttm)-71.43M
Shares Out47.92M
EPS (ttm)-1.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume57,543
Average Volume148,555
Open11.15
Previous Close11.10
Day's Range10.50 - 11.25
52-Week Range1.80 - 13.95
Beta0.05
RSI56.06
Earnings DateFeb 20, 2026

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.